Prof. P. Yogeeswari received her Ph.D. degree in the year 2001 from Banaras Hindu University, Varanasi, India. She has been in the field of drug discovery for neurological diseases and cancer for the past 16 years and has completed sponsored projects worth of 3 crores of rupees including industrial consultancy. She has also been granted IASP 2014 award for “Excellence in Pain Research and Management in Developing Countries” under the basic science research category to be received at the “15th World Congress on Pain” at Argentina in October 2014. She has collaborations with various national and international organizations. To her credit she holds more than 250 research publications with one granted Indian Patent and 4 Indian Patent applications. She has published a textbook on Medicinal Chemistry and authored book chapters. She is also currently a Co-Founder and Scientific advisor of a startup company.
The problem currently focused to be presented in the conference is a dream project for the cure for Breast cancer including triple negative type for which there are no drugs and few are in pipeline. Breast cancer being the deadliest cancer there is a need to develop an innovative preclinical drug candidate for breast cancer which is growing in numbers based on statistics. The drug candidate that we have identified disrupts an important protein overexpressed in breast cancer including triple negative type and also has an additional anti-angiogenic property which when combined are fruitful in combatting cancer more effectively and prevents metastasis. The drug discovery efforts for triple negative breast cancer seem to be really challenging and there are few innovative targets that are in pipeline and some are being less exploited. The speaker would give an overall insight on the drug discovery strategies to treat triple negative breast cancer.